Trials / Completed
CompletedNCT00191711
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
Phase II Study of 6 Weeks Intravesical Gemcitabine Instillation Followed By Transurethral Resection in Patients Affected By Superficial Bladder Cancer at Low Risk
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether neoadjuvant intravesical Gemcitabine is enough active in patients with a solitary, low risk superficial bladder cancer.After diagnostic urethrocystoscopy or bladder sonography, all patients will receive intravesical gemcitabine once a week during 6 weeks. Two weeks after finishing antiblastic therapy, all patients will be submitted to a new cystoscopy, with TUR or cold biopsies of the site of the initial lesion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine |
Timeline
- Start date
- 2004-02-01
- Completion
- 2005-10-01
- First posted
- 2005-09-19
- Last updated
- 2007-01-26
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00191711. Inclusion in this directory is not an endorsement.